Using Implementation Science to Reduce the Impact of RSV Disease on Infants, Families, and the Healthcare System

Interactive Practice Guide

Each year, respiratory syncytial virus (RSV) leads to over 2 million outpatient visits, up to 80,000 hospitalizations, and as many as 300 deaths among children younger than age 5. And, while prematurity and certain health problems increase the risk for severe RSV infection, most children hospitalized for RSV in the United States have no underlying health conditions or history of preterm birth. Available guidance recommends that clinicians provide RSV prophylaxis to all infants aged <8 months during their first RSV season and to high-risk children during their second season. The availability of novel preventive approaches and new guidance, as well as the recent approval of a maternal RSV vaccine, has created questions amongst clinicians. To answer these questions, this activity offers synergistic education and practical guidance to easily incorporate into routine clinical decision-making processes.

Faculty: Joseph Domachowske, MD, Tina Q. Tan, MD

Release Date: May 17, 2024

Expiration Date: May 17, 2025